KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Aquestive Therapeutics (AQST) Receivables - Other (2017 - 2025)

Aquestive Therapeutics has reported Receivables - Other over the past 9 years, most recently at $9.8 million for Q4 2025.

  • Quarterly results put Receivables - Other at $9.8 million for Q4 2025, up 294.26% from a year ago — trailing twelve months through Dec 2025 was $9.8 million (up 294.26% YoY), and the annual figure for FY2025 was $9.8 million, up 294.26%.
  • Receivables - Other for Q4 2025 was $9.8 million at Aquestive Therapeutics, up from $2.3 million in the prior quarter.
  • Over the last five years, Receivables - Other for AQST hit a ceiling of $9.8 million in Q4 2025 and a floor of $718000.0 in Q1 2025.
  • Median Receivables - Other over the past 5 years was $2.3 million (2025), compared with a mean of $2.9 million.
  • Biggest five-year swings in Receivables - Other: crashed 64.35% in 2022 and later soared 294.26% in 2025.
  • Aquestive Therapeutics' Receivables - Other stood at $6.0 million in 2021, then crashed by 64.35% to $2.1 million in 2022, then soared by 36.28% to $2.9 million in 2023, then fell by 15.16% to $2.5 million in 2024, then soared by 294.26% to $9.8 million in 2025.
  • The last three reported values for Receivables - Other were $9.8 million (Q4 2025), $2.3 million (Q3 2025), and $2.2 million (Q2 2025) per Business Quant data.